Incidence, Timing, and Management of Infections in Patients Receiving Daratumumab for the Treatment of Newly Diagnosed Transplant-Ineligible Multiple Myeloma in the MAIA Study

被引：0

作者：

Bahlis, Nizar J. ^{[1
]}

Facon, Thierry ^{[2
,3
]}

Usmani, Saad ^{[4
]}

Moreau, Philippe ^{[5
]}

Raje, Noopur ^{[6
]}

Zweegman, Sonja ^{[7
]}

Chari, Ajai ^{[8
]}

Perrot, Aurore ^{[9
]}

Manier, Salomon ^{[10
]}

Orlowski, Robert ^{[11
]}

Goldschmidt, Hartmut ^{[12
]}

Basu, Supratik ^{[13
,14
]}

Hulin, Cyrille ^{[15
]}

Weisel, Katja ^{[16
]}

Mohty, Mohamad ^{[17
,18
]}

Plesner, Torben ^{[19
,20
]}

Cook, Gordon ^{[21
]}

Leleu, Xavier ^{[22
]}

Quach, Hang ^{[23
]}

Venner, Christopher P. ^{[24
]}

Ngo, Mai ^{[25
]}

Bolyard, Kasey ^{[25
]}

Carson, Robin ^{[25
]}

Borgsten, Fredrik ^{[25
]}

Kumar, Shaji ^{[25
,26
]}

机构：

[1] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[2] Univ Lille, & French Acad Med, Dept Haematol, Paris, France

[3] French Acad Med, Paris, France

[4] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, New York, NY USA

[5] Univ Hosp Hotel Dieu, Dept Hematol, Hotel Dieu, France

[6] Massachusetts Gen Hosp, Boston, MA 02114 USA

[7] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Hematol, Amsterdam, Netherlands

[8] Univ Calif San Francisco, San Francisco, CA USA

[9] Ctr Hosp Univ Toulouse, Serv Hematol, Toulouse, France

[10] Univ Lille, Serv Hematol, CHU Lille, Hop Huriez, Lille, France

[11] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[12] Univ Hosp Heidelberg, GMMG Study Grp, Dept Internal Med, Heidelberg, Germany

[13] Royal Wolverhampton NHS Trust, Wolverhampton, W Midlands, England

[14] Wolverhampton Univ, CRN West Midlands, NIHR, Wolverhampton, W Midlands, England

[15] Hop Haut Leveque, Univ Hosp, Dept Hematol, Bordeaux, France

[16] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[17] Sorbonne Univ, Hop St Antoine, Paris, France

[18] INSERM, UMRS938, Paris, France

[19] Vejle Hosp & Univ Southern Denmark, Vejle, Denmark

[20] Univ Southern Denmark, Odense, Denmark

[21] Univ Leeds, Leeds Inst Clin Trials Res, Canc Res UK Clin Trials Unit, Leeds, W Yorkshire, England

[22] CHU Poitiers, Hematol, PRC, Poitiers, France

[23] Univ Melbourne, St Vincents Hosp Melbourne, Melbourne, Vic, Australia

[24] Univ Alberta, Cross Canc Inst, Dept Med Oncol, Edmonton, AB, Canada

[25] Janssen Res Dev LLC, Lower Gwynedd Township, PA USA

[26] Mayo Clin, Rochester, NY USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-324

引用

页码：S221 / S221

页数：1

共 50 条

[1] Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis
Facon, Thierry
Kumar, Shaji K.
Weisel, Katja
Usmani, Saad
Moreau, Philippe
Plesner, Torben
Orlowski, Robert Z.
Bahlis, Nizar Jacques
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Carson, Robin
Borgsten, Fredrik
Goldschmidt, Hartmut
BLOOD, 2022, 140 : 10133 - 10136
[2] Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
Facon, Thierry
Cook, Gordon
Usmani, Saad Z.
Hulin, Cyrille
Kumar, Shaji
Plesner, Torben
Touzeau, Cyrille
Bahlis, Nizar J.
Basu, Supratik
Nahi, Hareth
Goldschmidt, Hartmut
Quach, Hang
Mohty, Mohamad
Venner, Christopher P.
Weisel, Katja
Raje, Noopur
Hebraud, Benjamin
Belhadj-Merzoug, Karim
Benboubker, Lotfi
Decaux, Olivier
Manier, Salomon
Caillot, Denis
Ukropec, Jon
Pei, Huiling
Van Rampelbergh, Rian
Uhlar, Clarissa M.
Kobos, Rachel
Zweegman, Sonja
LEUKEMIA, 2022, 36 (04) : 1066 - 1077
[3] Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
Thierry Facon
Gordon Cook
Saad Z. Usmani
Cyrille Hulin
Shaji Kumar
Torben Plesner
Cyrille Touzeau
Nizar J. Bahlis
Supratik Basu
Hareth Nahi
Hartmut Goldschmidt
Hang Quach
Mohamad Mohty
Christopher P. Venner
Katja Weisel
Noopur Raje
Benjamin Hebraud
Karim Belhadj-Merzoug
Lotfi Benboubker
Olivier Decaux
Salomon Manier
Denis Caillot
Jon Ukropec
Huiling Pei
Rian Van Rampelbergh
Clarissa M. Uhlar
Rachel Kobos
Sonja Zweegman
Leukemia, 2022, 36 : 1066 - 1077
[4] Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Yahiya Y. Syed
Drugs, 2019, 79 : 447 - 454
[5] Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Syed, Yahiya Y.
DRUGS, 2019, 79 (04) : 447 - 454
[6] Treatment duration and long-term outcomes with daratumumab in transplant-ineligible newly diagnosed multiple myeloma from the phase 3 MAIA study
Moreau, Philippe
Facon, Thierry
Usmani, Saad
Kumar, Shaji
Plesner, Torben
Goldschmidt, Hartmut
Orlowski, Robert
Perrot, Aurore
Chari, Ajai
Cook, Gordon
Pei, Huiling
Van Rampelbergh, Rian
Bartlett, J. Blake
Uhlar, Clarissa
Carson, Robin
Bahlis, Nizar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S23 - S24
[7] Incidence of herpes zoster in transplant-ineligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone
Horigome, Yuichi
Kamata, Hirotoshi
Michishita, Yusuke
Yokoyama, Maki
Tadera, Noriyuki
Hayama, Kei
Suzuki, Takahiro
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025,
[8] Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes
Facon, Thierry
Moreau, Philippe
Weisel, Katja
Goldschmidt, Hartmut
Usmani, Saad Z.
Chari, Ajai
Plesner, Torben
Orlowski, Robert Z.
Bahlis, Nizar
Basu, Supratik
Hulin, Cyrille
Quach, Hang
O'Dwyer, Michael
Perrot, Aurore
Jacquet, Caroline
Venner, Christopher P.
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Cook, Gordon
Wang, George
Pei, Huiling
Krevvata, Maria
Carson, Robin
Borgsten, Fredrik
Kumar, Shaji K.
LEUKEMIA, 2025, : 942 - 950
[9] Quadruplets in newly diagnosed transplant-ineligible multiple myeloma
Chakraborty, Rajshekhar
Mian, Hira
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (11) : 2249 - 2252
[10] Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study
Takamatsu, Hiroyuki
Iida, Shinsuke
Shibayama, Hirohiko
Shibayama, Kazuhiro
Yamazaki, Hiroshi
Suzuki, Kenshi
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (05) : 692 - 701

← 1 2 3 4 5 →